Cantor Fitzgerald Predicts TSE:ONC FY2024 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Equities research analysts at Cantor Fitzgerald lowered their FY2024 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings of ($0.42) per share for the year, down from their prior estimate of ($0.36). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday.

Oncolytics Biotech Stock Down 2.1 %

ONC stock opened at C$1.38 on Monday. The firm has a market capitalization of C$106.07 million, a PE ratio of -3.63 and a beta of 1.35. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. Oncolytics Biotech has a twelve month low of C$1.15 and a twelve month high of C$2.32. The stock’s 50 day moving average is C$1.50 and its 200-day moving average is C$1.45.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.